Authoritative information and practical advice from the nation's cancer experts about mycosis fungoides and the Sezary syndrome includes official medical data on signs, symptoms, early detection, diagnostic testing, risk factors and prevention, treatment options, surgery, radiation, drugs, chemotherapy, staging, biology, prognosis, and survival, with a complete glossary of technical medical terms and current references.

Starting with the basics, and advancing to detailed patient-oriented and physician-quality information, this comprehensive in-depth compilation gives empowered patients, families, caregivers, nurses, and physicians the knowledge they need to understand the diagnosis and treatment of mycosis fungoides.

Comprehensive data on clinical trials is included - with information on intervention, sponsor, gender, age group, trial phase, number of enrolled patients, funding source, study type, study design, NCT identification number and other IDs, first received date, start date, completion date, primary completion date, last updated date, last verified date, associated acronym, and outcome measures.

Mycosis fungoides and the Sézary syndrome are diseases in which lymphocytes (a type of white blood cell) become malignant (cancerous) and affect the skin.

In mycosis fungoides, T-cell lymphocytes become cancerous and affect the skin. In the Sézary syndrome, cancerous T-cell lymphocytes affect the skin and the peripheral blood. Mycosis fungoides and the Sézary syndrome are types of cutaneous T-cell lymphoma. A possible sign of mycosis fungoides and the Sézary syndrome is a red rash on the skin.

Mycosis fungoides and the Sézary syndrome may move through the following phases: